Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Innovent doses first patient in Phase III sintilimab trial for NSCLC

Poorly differentiated non-small cell carcinoma NOS with a massive host inflammatory response. Credit: Yale Rosen.



Go Top